Russia’s Enteromix cancer vaccine, developed using mRNA technology, has shown 100 percent efficacy in early trials. Not yet approved for clinical use, it offers a personalised approach to training the immune system to target cancer cells
  • Truscape@lemmy.blahaj.zoneEnglish
    32·
    7 days ago

    If the world diversifies locations for medical research sites, that can only be a good thing for humanity as a whole.